MB 66

Drug Profile

MB 66

Alternative Names: HIV/HSV microbicide - Mapp; Mapp 66; MB66

Latest Information Update: 08 Feb 2016

Price : $50

At a glance

  • Originator Mapp Biopharmaceutical
  • Developer Boston University; Integrated Preclinical/Clinical Program for HIV Topical Microbicides Consortium; Mapp Biopharmaceutical; The Miriam Hospital
  • Class Monoclonal antibodies
  • Mechanism of Action HIV envelope protein gp120 inhibitors; HIV envelope protein gp41 inhibitors; HIV fusion inhibitors; Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Herpes simplex virus infections; HIV infections

Most Recent Events

  • 01 Jan 2016 Phase-I clinical trials in HIV infections in USA (Vaginal) (NCT02579083)
  • 09 Oct 2015 LeafBio plans the phase I VAST trial for HIV infections and Herpes simplex virus infections in USA (NCT02579083)
  • 23 Jan 2015 Preclinical trials in Herpes simplex virus infections prevention in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top